news9 November 2022 | By Catherine Eckford (European Pharmaceutical Review)
Bepirovirsen, an antisense oligonucleotide therapy aided in long-term prevention of chronic hepatitis B in patients on and not on nucleoside/nucleotide analogues in a Phase II trial.